EUVIMEDEUVIMED entdecken
Crossref

Low-Grade Myofibroblastic Sarcoma Represents an Epigenetically Distinct Myofibroblastic Tumor With USP6 Upregulation and Stable Genome

Maximus C F Yeung, Horace M H Cheung, Anthony P Y Liu, Tony W H Shek

Modern Pathology · 2026-06 · 39 (6) · 100998

DOI: 10.1016/j.modpat.2026.100998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-06. Verfasst von Maximus C F Yeung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Sp…. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Proto-Oncogene Proteins, Epigenesis, Genetic, Sarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: The University of Hong Kong Li Ka Shing Faculty of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low-grade myofibroblastic sarcoma (LGMS) is a rare, indolent mesenchymal neoplasm exhibiting myofibroblastic differentiation, with a propensity for local recurrence. The molecular basis of LGMS and its precise relationship with other histological mimics have remained largely undefined. To address this gap, we conducted the first comprehensive multiomics analysis of 6 LGMS cases, integrating whole-exome sequencing, RNA sequencing, and Illumina Methylation EPICv2 array profiling with comparative analysis against public sarcoma methylation cohorts and related fibroblastic tumors. Clinically, patients (median age 35.5 years) presented with small tumors (median size 1.45 cm), predominantly located in the head and neck, displaying classic histological features of diffusely infiltrative spindle cell fascicles with patchy mononuclear inflammation. Two of the 5 patients with follow-up developed local recurrence, and none metastasized (median follow-up duration 92.5 months). Genomically, all LGMS exhibited a low tumor mutational burden (median 2.31 mut/Mb) and a minimal fraction of genome altered, with TP53 and TSC2 deletions and NTRK1 and ERBB3 amplifications found in a subset of cases. No pathogenic fusions were detected. Transcriptomic profiling revealed a distinct signature featuring prominent USP6 overexpression and upregulation of inflammatory and immune-related genes, including CD274 (PD-L1), and enrichment of inflammatory and interferon-gamma response signatures. Epigenetically, LGMS formed a unique methylation cluster closest to inflammatory myofibroblastic tumor, with numerous differentially methylated regions and higher immune infiltration, particularly monocytes, compared with other fibroblastic tumors. These findings establish LGMS as a genomically stable, epigenetically distinct myofibroblastic sarcoma driven by USP6 overexpression and an inflammation-enriched transcriptome. They support its recognition as a standalone entity, facilitate integration into methylation-based sarcoma classifiers for improved diagnostic precision, and nominate USP6-associated pathways and immune checkpoint blockade as promising therapeutic strategies for recurrent or unresectable disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin ThiolesteraseProto-Oncogene ProteinsEpigenesis, GeneticSarcomaBiomarkers, TumorHumansFemaleAdultMaleUp-RegulationMiddle AgedYoung AdultMyofibroblastsDNA Methylation

Stichwörter der Autor:innen

USP6low-grade myofibroblastic sarcomamethylationmolecularmultiomics

Substanzen

Ubiquitin ThiolesteraseUSP6 protein, humanProto-Oncogene ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China. Electronic address: mcfyeung@hku.h…
  • Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
  • Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Förderung

  • The University of Hong Kong Li Ka Shing Faculty of Medicine

Zitieren

APA

Yeung, M. C. F., Cheung, H. M. H., Liu, A. P. Y., & Shek, T. W. H. (2026). Low-Grade Myofibroblastic Sarcoma Represents an Epigenetically Distinct Myofibroblastic Tumor With USP6 Upregulation and Stable Genome. Modern Pathology, 39(6), 100998. https://doi.org/10.1016/j.modpat.2026.100998

Vancouver

Yeung MCF, Cheung HMH, Liu APY, Shek TWH. Low-Grade Myofibroblastic Sarcoma Represents an Epigenetically Distinct Myofibroblastic Tumor With USP6 Upregulation and Stable Genome. Modern Pathology. 2026;39(6):100998. doi:10.1016/j.modpat.2026.100998

BibTeX
@article{Yeung2026,
  author = {Yeung, Maximus C F and Cheung, Horace M H and Liu, Anthony P Y and Shek, Tony W H},
  title = {Low-Grade Myofibroblastic Sarcoma Represents an Epigenetically Distinct Myofibroblastic Tumor With USP6 Upregulation and Stable Genome},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {6},
  pages = {100998},
  doi = {10.1016/j.modpat.2026.100998}
}
Kostenlos starten →